Trial Search Results
Platelet Rich Plasma for Patients With Recurrent Implantation Failure
Patients with recurrent implantation failure are among the most difficult patients to treat, with no proven standard treatment. Platelet rich plasma stimulates cellular processes involved in endometrial regeneration, and in a small case series has shown efficacy for this patient population. We hope to conduct a randomized controlled pilot study to determine whether PRP is indeed an effective treatment for recurrent implantation failure.
Stanford is currently accepting patients for this trial.
- Combination Product: Platelet rich plasma
- Combination Product: Placebo
Early Phase 1
- All women who have undergone 3 or more embryo (blastocyst stage) transfers without
establishing a clinical pregnancy or 2 or more euploid embryo transfers without
establishing a clinical pregnancy, aged 18 - 45, with a normal uterine cavity
established within 12 months by hysteroscopy or saline infusion sonogram, planning in
vitro fertilization with an embryo transfer at Stanford Fertility and Reproductive
Health. The planned transfer must consist of any of the following: a PGS proven
euploid embryo, a good quality blastocyst from a patient younger than 37, or a donor
- Abnormal uterine cavity, planning in vitro fertilization with use of a gestational
carrier. patients enrolled in other experimental interventions for RIF will be
excluded. Patients with only poor quality or cleavage stage embryos.
Ages Eligible for Study
18 Years - 45 Years
Genders Eligible for Study